Join
Live feed
·
PRReleasevia Quantisnow
Aprea Therapeutics Inc. logo

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

ByQuantisnow·Wall Street's wire, on your screen.
APRE· Aprea Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track APRE (Aprea Therapeutics Inc.) and more on Quantisnow.